Ninlaro (ixazomib) vs Darzalex (daratumumab)
Ninlaro (ixazomib) vs Darzalex (daratumumab)
Ninlaro (ixazomib) and Darzalex (daratumumab) are both used in the treatment of multiple myeloma, but they work in different ways and have different administration methods. Ninlaro is an oral proteasome inhibitor that interferes with the cellular mechanisms that promote the survival of myeloma cells, while Darzalex is an intravenous monoclonal antibody that targets and kills myeloma cells by recognizing a specific protein on their surface. The choice between these medications would depend on the patient's specific medical condition, treatment history, and the presence of any contraindications, as well as the preference for an oral versus intravenous administration, which should be discussed with a healthcare provider.
Difference between Ninlaro and Darzalex
Metric | Ninlaro (ixazomib) | Darzalex (daratumumab) |
---|---|---|
Generic name | Ixazomib | Daratumumab |
Indications | Multiple myeloma | Multiple myeloma |
Mechanism of action | Proteasome inhibitor | CD38-directed cytolytic antibody |
Brand names | Ninlaro | Darzalex |
Administrative route | Oral | Intravenous |
Side effects | Thrombocytopenia, gastrointestinal issues, peripheral neuropathy, rash | Infusion reactions, neutropenia, thrombocytopenia, upper respiratory tract infection |
Contraindications | Hypersensitivity to ixazomib or any of its excipients | Hypersensitivity to daratumumab or any of its excipients |
Drug class | Proteasome inhibitor | Monoclonal antibody |
Manufacturer | Takeda Pharmaceuticals | Janssen Biotech |
Efficacy
Ninlaro (Ixazomib) in the Treatment of Multiple Myeloma
Ninlaro (ixazomib) is an oral proteasome inhibitor approved for the treatment of multiple myeloma. It is typically used in combination with lenalidomide and dexamethasone for patients who have received at least one prior therapy. The efficacy of Ninlaro was demonstrated in a pivotal phase 3 clinical trial known as the TOURMALINE-MM1 study. In this study, patients treated with the combination of ixazomib, lenalidomide, and dexamethasone had a significantly longer progression-free survival (PFS) compared to patients who received lenalidomide and dexamethasone alone. The median PFS for patients receiving Ninlaro was 20.6 months compared to 14.7 months for those who did not receive the drug, indicating a clear benefit in delaying disease progression.
Darzalex (Daratumumab) in the Treatment of Multiple Myeloma
Darzalex (daratumumab) is a monoclonal antibody that targets CD38, a surface protein that is highly expressed on multiple myeloma cells. Daratumumab is used as a monotherapy or in combination with other treatments such as lenalidomide, bortezomib, and dexamethasone. The efficacy of Darzalex has been evaluated in several clinical trials, showing significant improvement in patient outcomes. In a key study, patients receiving daratumumab in combination with lenalidomide and dexamethasone had a 63% reduction in the risk of disease progression or death compared to the control group. Furthermore, the addition of daratumumab to standard regimens has been associated with higher rates of complete response and very good partial response.
Comparative Efficacy in Multiple Myeloma
When comparing the efficacy of Ninlaro and Darzalex, it is important to consider that they are often used in different lines of therapy and in combination with different agents, making direct comparisons challenging. However, both drugs have individually shown to improve outcomes in multiple myeloma patients. The choice of therapy may depend on various factors, including previous treatments, patient health status, and specific genetic markers of the disease. Physicians may choose to use these medications in sequence or in combination, depending on the individual patient's response and tolerance to treatment.
Conclusion
In conclusion, both Ninlaro and Darzalex have proven to be effective in the treatment of multiple myeloma, offering patients additional options to manage this complex and often refractory disease. Their incorporation into treatment regimens has contributed to the improvement of progression-free survival and overall response rates in multiple myeloma patients. Ongoing research and clinical trials continue to refine the use of these drugs and explore their full potential in combination therapies for better patient outcomes.
Regulatory Agency Approvals
Ninlaro
Darzalex
Access Ninlaro or Darzalex today
If Ninlaro or Darzalex are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us